Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.

[1]  Jinming Yu,et al.  CIP2A is overexpressed in esophageal squamous cell carcinoma , 2012, Medical Oncology.

[2]  C. Teng,et al.  MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis , 2012, Oncogene.

[3]  K. Friese,et al.  Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. , 2011, Current cancer drug targets.

[4]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[5]  Guang-Biao Zhou,et al.  Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer , 2011, PloS one.

[6]  Xinjun Dong,et al.  CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis , 2011, Annals of Surgical Oncology.

[7]  M. Odero,et al.  PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect , 2011, Leukemia.

[8]  A. Cheng,et al.  CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells , 2010, Oncogene.

[9]  A. Ristimäki,et al.  CIP2A expression is increased in prostate cancer , 2010, Journal of experimental & clinical cancer research : CR.

[10]  T. Pugh,et al.  Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. , 2010, International journal of radiation oncology, biology, physics.

[11]  Tepper,et al.  A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. , 2010, Clinical colorectal cancer.

[12]  O. Kallioniemi,et al.  CIP2A Is Associated with Human Breast Cancer Aggressivity , 2009, Clinical Cancer Research.

[13]  Q. Dou,et al.  Clinical development of novel proteasome inhibitors for cancer treatment , 2009, Expert opinion on investigational drugs.

[14]  W. Curran,et al.  Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. , 2009, International journal of radiation oncology, biology, physics.

[15]  H. Hsieh,et al.  Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway* , 2009, Journal of Biological Chemistry.

[16]  B. Dirican,et al.  Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. , 2009, Urology.

[17]  M. Pomper,et al.  Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors , 2008, Nature Medicine.

[18]  M. Herlyn,et al.  Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway , 2008, Molecular Cancer Therapeutics.

[19]  Kuen-Feng Chen,et al.  Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. , 2008, Cancer research.

[20]  Tao Wang,et al.  [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]. , 2008, Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery.

[21]  R. Sears,et al.  CIP2A Inhibits PP2A in Human Malignancies , 2007, Cell.

[22]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[23]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[24]  P. Olive,et al.  The role of DNA single- and double-strand breaks in cell killing by ionizing radiation. , 1998, Radiation research.

[25]  Kuen-Feng Chen,et al.  Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. , 2010, Journal of hepatology.

[26]  A. Dicker,et al.  Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341) , 2008, Archives of Gynecology and Obstetrics.